

# Mar Gil

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/7178050/mar-gil-publications-by-year.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

38  
papers

2,154  
citations

20  
h-index

46  
g-index

48  
ext. papers

2,657  
ext. citations

4.2  
avg, IF

5.35  
L-index

| #  | Paper  | IF   | Citations |
|----|--|------|-----------|
| 38 | Reply.. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2022</b> , 59, 274   | 5.8  |           |
| 37 | Risk of fetal loss after chorionic villus sampling in twin pregnancies derived from propensity score matching analysis. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2021</b> ,   | 5.8  | 2         |
| 36 | Acceptability of Clinical Trials on COVID-19 during Pregnancy among Pregnant Women and Healthcare Providers: A Qualitative Study. <i>International Journal of Environmental Research and Public Health</i> , <b>2021</b> , 18,                                   | 4.6  | 3         |
| 35 | Cell-free DNA testing of maternal blood in screening for trisomies in twin pregnancy: updated cohort study at 10-14 weeks and meta-analysis. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2021</b> , 58, 178-189  | 5.8  | 7         |
| 34 | Scientific effort in combating COVID-19 in obstetrics and gynecology. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2021</b> , 57, 189-194   | 5.8  | 0         |
| 33 | Pravastatin Versus Placebo in Pregnancies at High Risk of Term Preeclampsia. <i>Circulation</i> , <b>2021</b> , 144, 670-679   | 16.7 | 14        |
| 32 | Percutaneous fetoscopic spina bifida repair: effect on ambulation and need for postnatal cerebrospinal fluid diversion and bladder catheterization. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2021</b> , 58, 582-589                                   | 5.8  | 5         |
| 31 | Effect of coronavirus disease 2019 (COVID-19) on maternal, perinatal and neonatal outcome: systematic review. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2020</b> , 56, 15-27   | 5.8  | 243       |
| 30 | Hydroxychloroquine efficacy and safety in preventing SARS-CoV-2 infection and COVID-19 disease severity during pregnancy (COVID-Preg): a structured summary of a study protocol for a randomised placebo controlled trial. <i>Trials</i> , <b>2020</b> , 21, 607 | 2.8  | 5         |
| 29 | Reply. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2020</b> , 55, 696-697  | 5.8  |           |
| 28 | Genome-wide cfDNA testing of maternal blood. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2020</b> , 55, 13-14  | 5.8  | 8         |
| 27 | Clinical and Economic Evaluation after Adopting Contingent Cell-Free DNA Screening for Fetal Trisomies in South Spain. <i>Fetal Diagnosis and Therapy</i> , <b>2020</b> , 1-8  | 2.4  | 0         |
| 26 | Is it possible to predict late antepartum stillbirth by means of cerebroplacental ratio and maternal characteristics?. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2020</b> , 33, 2996-3002  | 2    | 2         |
| 25 | Does low-dose aspirin initiated before 11 weeksUgestation reduce the rate of preeclampsia?. <i>American Journal of Obstetrics and Gynecology</i> , <b>2020</b> , 222, 437-450  | 6.4  | 20        |
| 24 | New approach for estimating risk of miscarriage after chorionic villus sampling. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2020</b> , 56, 656-663  | 5.8  | 6         |
| 23 | Screening for trisomies by cfDNA testing of maternal blood in twin pregnancy: update of The Fetal Medicine Foundation results and meta-analysis. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2019</b> , 53, 734-742                                      | 5.8  | 50        |
| 22 | First-trimester screening for trisomies by cfDNA testing of maternal blood in singleton and twin pregnancies: factors affecting test failure. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2019</b> , 53, 804-809   | 5.8  | 25        |

|    |   |     |     |
|----|---|-----|-----|
| 21 | Implementation of Maternal Blood Cell Free DNA Testing in Early Screening for Aneuploidies. <i>Maternal-Fetal Medicine</i> , <b>2019</b> , 1, 2-6   | 0.6 | 1   |
| 20 | Implementation of maternal blood cell-free DNA testing in early screening for aneuploidies. <i>Medizinische Genetik</i> , <b>2019</b> , 31, 283-288   | 0.5 |     |
| 19 | Routine first-trimester screening for fetal trisomies in twin pregnancy: cell-free DNA test contingent on results from combined test. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2019</b> , 53, 208-213                      | 5.8 | 21  |
| 18 | Classification of Uterine Anomalies by 3-Dimensional Ultrasonography Using ESHRE/ESGE Criteria: Interobserver Variability. <i>Reproductive Sciences</i> , <b>2018</b> , 25, 740-747   | 3   | 7   |
| 17 | Analysis of cell-free DNA in maternal blood in screening for aneuploidies: updated meta-analysis. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2017</b> , 50, 302-314  | 5.8 | 315 |
| 16 | Screening for trisomies 21 and 18 in a Spanish public hospital: from the combined test to the cell-free DNA test. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2017</b> , 30, 2476-2482                                | 2   | 7   |
| 15 | Clinical implementation of routine screening for fetal trisomies in the UK NHS: cell-free DNA test contingent on results from first-trimester combined test. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2016</b> , 47, 45-52 | 5.8 | 79  |
| 14 | Reply. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2016</b> , 47, 789   | 5.8 |     |
| 13 | Analysis of cell-free DNA in maternal blood in screening for fetal aneuploidies: updated meta-analysis. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2015</b> , 45, 249-66   | 5.8 | 353 |
| 12 | UK NHS pilot study on cell-free DNA testing in screening for fetal trisomies: factors affecting uptake. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2015</b> , 45, 67-73  | 5.8 | 32  |
| 11 | Performance of screening for aneuploidies by cell-free DNA analysis of maternal blood in twin pregnancies. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2015</b> , 45, 61-6  | 5.8 | 87  |
| 10 | Screening for trisomies 21, 18 and 13 by cell-free DNA analysis of maternal blood at 10-11 weeksU gestation and the combined test at 11-13 weeks. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2015</b> , 45, 36-41            | 5.8 | 79  |
| 9  | Use of intrapartum ultrasound in the prediction of complicated operative forceps delivery of fetuses in non-occiput posterior position. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2014</b> , 43, 687-92                     | 5.8 | 44  |
| 8  | Cell-free DNA analysis for trisomy risk assessment in first-trimester twin pregnancies. <i>Fetal Diagnosis and Therapy</i> , <b>2014</b> , 35, 204-11   | 2.4 | 78  |
| 7  | Analysis of cell-free DNA in maternal blood in screening for aneuploidies: meta-analysis. <i>Fetal Diagnosis and Therapy</i> , <b>2014</b> , 35, 156-73   | 2.4 | 109 |
| 6  | First-trimester contingent screening for trisomies 21, 18 and 13 by biomarkers and maternal blood cell-free DNA testing. <i>Fetal Diagnosis and Therapy</i> , <b>2014</b> , 35, 185-92  | 2.4 | 40  |
| 5  | Assessment of fetal sex chromosome aneuploidy using directed cell-free DNA analysis. <i>Fetal Diagnosis and Therapy</i> , <b>2014</b> , 35, 1-6   | 2.4 | 66  |
| 4  | Prenatal detection of fetal triploidy from cell-free DNA testing in maternal blood. <i>Fetal Diagnosis and Therapy</i> , <b>2014</b> , 35, 212-7  | 2.4 | 80  |

|   |   |     |     |
|---|---|-----|-----|
| 3 | Validation of targeted sequencing of single-nucleotide polymorphisms for non-invasive prenatal detection of aneuploidy of chromosomes 13, 18, 21, X, and Y. <i>Prenatal Diagnosis</i> , <b>2013</b> , 33, 575-9 | 3.2 | 174 |
| 2 | Implementation of maternal blood cell-free DNA testing in early screening for aneuploidies. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2013</b> , 42, 34-40  | 5.8 | 108 |
| 1 | First-trimester contingent screening for trisomy 21 by biomarkers and maternal blood cell-free DNA testing. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2013</b> , 42, 41-50                            | 5.8 | 83  |